v3.25.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jul. 04, 2025
Jan. 03, 2025
Current assets:    
Cash and cash equivalents $ 164,433 $ 217,374
Marketable securities 626,665 893,902
Trade receivables, net 292,354 265,437
Inventory 23,483 22,388
Prepaid expenses and other current assets 73,829 68,478
Total current assets 1,180,764 1,467,579
Non-current marketable securities 594,652 637,291
Property and equipment, net 110,314 119,391
Deferred tax assets, net 419,241 420,027
Goodwill 63,684 63,684
Right-of-use assets and other non-current assets 309,426 239,718
Total assets 2,678,081 2,947,690
Current liabilities:    
Accounts payable 25,821 38,191
Accrued compensation and benefits 72,250 109,830
Accrued clinical trial liabilities 57,874 57,976
Rebates and fees due to customers 57,276 62,376
Accrued collaboration liabilities 21,525 40,384
Other current liabilities 101,365 95,012
Total current liabilities 336,111 403,769
Non-current operating lease liabilities 179,842 190,823
Other non-current liabilities 128,592 108,895
Total liabilities 644,545 703,487
Commitments and contingencies (Note 11)
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 270,132 and 281,732 at June 30, 2025, and December 31, 2024, respectively 270 282
Additional paid-in-capital 2,251,456 2,343,915
Accumulated other comprehensive income (loss) 1,349 (1,347)
Accumulated deficit (219,539) (98,647)
Total stockholders’ equity 2,033,536 2,244,203
Total liabilities and stockholders’ equity $ 2,678,081 $ 2,947,690